Your session is about to expire
← Back to Search
Lanadelumab for Hemodialysis Complications (Hinder Trial)
Hinder Trial Summary
This trial is testing whether or not a drug called lanadelumab can help to prevent a condition called dialysis-induced hypotension, which is caused by low blood pressure during hemodialysis.
Hinder Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowHinder Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Hinder Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been on hemodialysis 3 times a week for over 6 months.I have been on stable dialysis with a specific filter for over 3 months.I experience a significant drop in blood pressure and symptoms like nausea or dizziness during dialysis.I have not had a serious infection in the last month.You have experienced low blood pressure four or more times in the past four weeks during hemodialysis sessions.I haven't taken immunosuppressive drugs in the last month.I have not had a serious bleeding event in the last 6 months.My liver disease is in an advanced stage.I am unable to give consent by myself.I need medication to manage low blood pressure during dialysis.I have not had a heart attack or stroke in the last 3 months.Your blood pressure is too high before dialysis.Your heart's pumping ability is very low (less than 30%).I am expecting to receive a kidney from a living donor.Your blood pressure before starting dialysis is between 110 and 170 mmHg.I have an active connective tissue disease.I need blood transfusions due to severe anemia.You have a history of not following your hemodialysis or other medical treatment plan.I am between 18 and 85 years old.
- Group 1: Lanadelumab
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Who is eligible to enroll in this medical trial?
"To gain admittance to this clinical trial, individuals must be receiving hemodialysis treatments and between the ages of 18-85. The researchers are recruiting approximately 32 participants in total."
What measures have been taken to guarantee the security of Lanadelumab Injection [Takhzyro] for subjects?
"Takhzyro's safety is rated as a 2 due to its Phase 2 clinical trial status, indicating that while there are some data points supporting its security, there are none affirming the efficacy of this injection."
Is this trial presently recruiting participants?
"Affirmative. Clinicaltrials.gov has verified that the research initiative, which was initially published on July 27th 2022, is actively recruiting patients. 32 participants are required at a single medical site."
What is the current population size of this scientific investigation?
"Affirmative. According to the clinicaltrials.gov portal, this medical trial is recruiting participants as of now. The research was initially posted on July 27th 2022 and its details were most recently revised on August 4th 2022 with a requirement for 32 subjects at 1 site."
Does this experiment include elderly citizens within its recruitment plan?
"To qualify for this medical trial, patients must between 18 and 85 years old. There are 8 distinct studies that include minors while 101 other trials cater to elderly participants."
Share this study with friends
Copy Link
Messenger